Patents by Inventor Angela Reynolds

Angela Reynolds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • siRNA targeting spleen tyrosine kinase
    Patent number: 7645869
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: January 12, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting polo-like Kinase-1 (PLK-1)
    Publication number: 20100004141
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PLK-1.
    Type: Application
    Filed: July 24, 2009
    Publication date: January 7, 2010
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting myeloid cell Leukemia sequence 1
    Publication number: 20100004142
    Abstract: Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Application
    Filed: August 12, 2009
    Publication date: January 7, 2010
    Applicant: DHARMACON INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
    Patent number: 7642349
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: January 5, 2010
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4)
    Publication number: 20090325818
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.
    Type: Application
    Filed: July 28, 2009
    Publication date: December 31, 2009
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting intercellular adhesion molecule 1 (ICAM1)
    Patent number: 7638622
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for ICAM1.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: December 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting insulin-like growth factor 1 receptor (IGF-1R)
    Patent number: 7638621
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to Insulin-Like Growth Factor 1 Receptor (IGF-1R).
    Type: Grant
    Filed: April 3, 2007
    Date of Patent: December 29, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting amyloid beta (A4) precursor protein (APP)
    Patent number: 7635771
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: December 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting protein kinase N-3 (PKN-3)
    Patent number: 7635770
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PKN-3.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: December 22, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting proto-oncogene MET
    Patent number: 7632939
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for proto-oncogene MET.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: December 15, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting superoxide dismutase 1 (SOD1)
    Patent number: 7632938
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for SOD1.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: December 15, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting TNFalpha
    Publication number: 20090306356
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to TNF?.
    Type: Application
    Filed: September 12, 2008
    Publication date: December 10, 2009
    Applicant: DHARMACON,INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting KRAS
    Publication number: 20090298176
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Application
    Filed: July 6, 2009
    Publication date: December 3, 2009
    Applicant: DHARMACON INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting transducin (beta)-like 3 (TBL3)
    Publication number: 20090291497
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TBL3.
    Type: Application
    Filed: July 1, 2009
    Publication date: November 26, 2009
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
    Patent number: 7619081
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to COPB2.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: November 17, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
    Publication number: 20090281297
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MYC.
    Type: Application
    Filed: June 16, 2009
    Publication date: November 12, 2009
    Applicant: DHARMACON, INC
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
    Publication number: 20090280567
    Abstract: RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5? terminal sense nucleotides with 2?-O-alkyl groups and a label on the first 5? terminal sense nucleotide, in conjunction with at least one additional 2?-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2? fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5? terminal antisense nucleotide; or (ii) a first and second 5? terminal antisense nucleotide with 2?-O-alkyl modifications and at least one additional 2?-O-alkyl pyrimidine modified antisense nucleotide.
    Type: Application
    Filed: June 17, 2009
    Publication date: November 12, 2009
    Applicant: DHARMACON, INC.
    Inventors: Devin Leake, Anastasia Khvorova, Yuriy Fedorov, Michael Owen Delaney, Barbara Robertson, Emily Anderson, Angela Reynolds
  • siRNA targeting TIE-2
    Patent number: 7615541
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: November 10, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting inner centromere protein antigens (INCENP)
    Publication number: 20090275640
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP.
    Type: Application
    Filed: May 12, 2009
    Publication date: November 5, 2009
    Applicant: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
    Patent number: 7612196
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 3, 2009
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe